COVID-19 Pandemic Coverage
XTalks
SEPTEMBER 14, 2020
Already in Phase III clinical trials, interim results from their Phase I/III COV001 trial showed that neutralizing antibody responses against SARS-CoV-2 were detected in 91 percent of participants after a single dose of the vaccine, and in all participants after a booster dose. Novavax’ COVID-19 Vaccine. Russia’s COVID-19 Vaccine.
92 
Let's personalize your content